Friday, 19 Oct 2018

You are here

RheumNow Week in Review – Vitamin D Falls Again (10.4.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com. 

  1. Medical marijuana use is up 83% (46K users) in Illinois -with sales of ~$12million/month. Use lead by PTSD (4000) which surpassed fibromyalgia (3400) and cancer (2500) https://t.co/NxizLBoJeC   
  2. Gabapentin (GABA) is 10th most Prescribed drug in USA; 22% of opioid abusers abuse GABA (also high in EU); off label use is pervasive; GABA assoc w/ overdose deaths in Tenn (4%), https://t.co/DHYeBfjgi1 (15%), NC (20%), KY (41%). Should it be Schedule V https://t.co/UVOB9Kif6S 
  3. ILAR/PRINTO Again wants to again redefine JIA - as 4 groups: a) systemic JIA; b) RF+ JIA; c) enthesitis/SpA-related JIA; d) early-onset ANA+ JIA. Hopefully subsets will differ in MOA, outcomes, Treatments and NOT all be reported together in the future.https://t.co/qjEuvsC873   
  4. Medicare claims data analysis compared 4,551 ESRD/Hemodialysis and 45,510 controls and showed that PPI and H2 blocker use was associated with a 25% and 23% increased risk of Hip fracture. https://t.co/h4lKO506yH 
  5. Twitter Poll: Often Not discussed but do you combine Otezla with a biologic (TNFi or IL-17 inhibitor) in your difficult PsA patients? Rheumatolgists poll – 81 respondents: 36% No/Never; 26% can’t get approval; 26% yes +benefits; 12% Yes but no benefit.   
  6. RCT Extended vs flexed knee positioning for arthrocentesis in 55 knees (20 vs 35) - Extended knee was 2X better in Syn fluid yield (16.9 vs 5.9 ml) and more succcessful at dx fluid aspiration (99% vs 77%). Mechanical compression equaled out these results. https://t.co/JfAjTDRBhG 
  7. ASPECT trial in 1250 Belgians shows a 20 and 30% increased risk of developing IBD & acute anterior uveitis, respectively after 10 yrs of axial SpA; IBD and AAU risk (not psoriasis) related to Dz duration and inflammation, https://t.co/BnMFCAKSSB 
  8. TCZ doesn’t meet primary end point in ph3 trial for AOSD but helps⬇️ steroid dose: ACR50 at wk 4 61.5% vs 30.8% PBO but p=0.24. Steroid dose ⬇️ by 46.2% in the TCZ vs 21.0% in PBO group (p=0.017). ACR 20/50/70 84.6%/84.6%/61.5% at wk52 https://t.co/Q9vrNsGb9F @RheumNow 
  9. JAMA study of 59 FDA approved drugs (138 pivotal RCTs) in 2015-2016 shows the median cost per trial to be $19 million (range, $5 million for uncontrolled 3 orphan drugs to $347 million for noninferiority trial). Noninferiority trials most expensive! https://t.co/F0X5V5I0RD   
  10. Vitamin D Fails to Improve Bone Health  
  11. Zolendronic Acid Benefits Elder Women with Osteopenia 
  12. Predictive Risk Factors for Uveitis in JIA

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Week in Review – ACR Preview Edition (10.19.18)

Dr. Jack Cush summarizes the news and reports from RheumNow.Com this past week and previews RheumNow activities at the upcoming ACR 2018 meeting in Chicago.

RheumNow Week in Review – Four Fingers are Best (10.12.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. New info on scleroderma-SLE overlap, nailfold capillaroscopy, Women with SpA, acute gout management and lupus patient in pain who visit the ED.

RheumNow Week in Review – I Wanna New Drug (9.28.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com, including news on inappropriate opioids, pre-clinical RA treatment, DMARDs in Gout, the decline of arthroscopy, and a pain in the mouth.

CDC: 2017 Record Number of Influenza Deaths

The CDC reports that in 2017, influenza killed and hospitalized more people in the United States than any other year in the last few decades. (Citation Source http://bit.ly/2DBr0TE)

RheumNow Week in Review – RheumNow Live Meeting Announcement (9.21.18)

Dr. Jack Cush reviews the news and updates from the past week on RheumNow.